Abstract
Traditionally, the objective of high-throughput screening (HTS) has been to identify compounds that interact with a defined target protein as the starting point for a chemistry lead optimisation programme. To enable this it has become commonplace to express the drug target in a recombinant expression system and use this reagent as the source of the biological material to support the HTS campaign. In this chapter we describe an alternative HTS methodology with the objective of identifying compounds that mediate a change in a defined physiological end point as a consequence of compound activity in human primary cells. Rather than screening at a defined molecular target, such “phenotypic” screens permit the identification of compounds that act at any target protein within the cell to regulate the end point under study. As an example of such a screen we will describe an HTS campaign to identify compounds that promote the production of the cytokine interferon-α from human blood peripheral mononuclear cells (PBMCs) isolated from whole blood. We describe the procedures required to obtain and purify human PBMCs and the electrochemiluminescence-based assay technology used to detect interferon-α and highlight the challenges associated with this screening paradigm.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Posner, B. A. (2005) High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Curr. Op. Drug Disc. Dev. 8, 487–494.
Gribbon, P. and Andreas, S. (2005) High-throughput drug discovery: What can we expect from HTS? Drug Disc. Today 10, 17–22.
Walters, W. P. and Namchuck, M. (2003) Designing screens: How to make your hits a hit. Nat. Rev. Drug Disc. 2, 259–266.
Moore, K. and Rees, S. (2001) Cell-based versus isolated target screening: How lucky do you feel? J. Biomol. Scr. 6, 66–74.
Horrocks, C., Halse, R., Suzuki, R., and Shepherd, P. A. (2003) Human cell systems for drug discovery. Curr. Op. Drug Disc. Dev. 6, 570–575.
Clemons P. A. (2004) Complex phenotypic assays in high-throughput screening. Curr. Op. Chem. Biol. 8, 334–338.
Rossi, C., Padmanaban, D., Ni, J., Yeh, L.-A., Glicksman, M., and Waldner, H. (2007) Identifying drug-like inhibitors of myelin-reactive T cells by phenotypic high-throughput screening of a small-molecule library. J. Biomol. Scr. 12, 481–489.
See http://www.meso-scale.com for literature describing the theory and application of electrochemiluminescence detection.
Seehttp://www.las.perkinelmer.com/ for literature describing the theory and application of AlphaLisa detection.
Gay, N. J. and Gangloff, M. (2007) Structure and function of Toll receptors and their ligands. Ann. Rev. Biochem. 76, 141–165.
Uematsu, S. and Akira, S. (2007) Toll-like receptors and type-1 interferons. J. Biol. Chem. 282, 15319–15324.
Weeratna, R. D., Makinen, S. R., McCluskie, M. J., and Davis, H. L. (2005) TLR agonists as vaccine adjuvants: Comparison of CpG ODN and Resiquimod (R-848). Vaccine 23, 5263–5270.
Gerondakis, S., Grumont, R. J., and Banerjee, A. (2007) Regulating B-cell activation and survival in response to TLR signals. Immunol. Cell Biol. 85, 471–475.
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., and Bauer, S. (2002) Human TLR7 or TLR8 independently confer responsiveness to the anti-viral compound R-848. Nat. Immunol. 3, 499–504.
Human Tissue Act (2004) available from http://www.opsi.gov.uk.
Zhang, J.-H., Chung, D. Y., and Oldenberg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Scr. 4, 67–73.
Kunapuli, P., Zheng, W., Weber, M., Solly, K., Mull, R., Platchek, M., Cong, M., Zhong, Z., and Strulovici, B. (2005) Application of division arrest technology to cell-based HTS: comparison with frozen and fresh cells. Assay & Drug Dev. Technol. 3, 17–26.
Smith, J. G., Joseph, H. R., Green, T., Field, J. A., Wooters, M., Kaufhold, R. M., Antonello, J., and Caulfield, M. J. (2007) Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clinical & Vaccine Immunol. 14, 527–537.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Dunne, A., Jowett, M., Rees, S. (2009). Use of Primary Human Cells in High-Throughput Screens. In: Janzen, W., Bernasconi, P. (eds) High Throughput Screening. Methods in Molecular Biology, vol 565. Humana Press. https://doi.org/10.1007/978-1-60327-258-2_12
Download citation
DOI: https://doi.org/10.1007/978-1-60327-258-2_12
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-257-5
Online ISBN: 978-1-60327-258-2
eBook Packages: Springer Protocols